

Balaxi Pharmaceuticals Limited

Date: 11.02.2025

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

NSE Symbol: BALAXI

Dear Sir/Madam,

Subject: Newspaper Advertisement – Disclosure under Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement published today i.e., February 11, 2025, regarding the financial results of the Company for the quarter ended December 31, 2024, as published in Business Standard (English) and Nava Telangana (Telugu) newspapers.

The aforesaid information is also being hosted on the Company's website at www.balaxipharma.in.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

Mohith Kumar Khandelwal
Company Secretary & Compliance Officer

Encl: A/a

Registered Office:

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in

MPL
MAITHON POWER LIMITED
(Contracts Department)
Maithon Power Ltd, Village: Dambhui,
PO Barbindia, PIN-828205, District-Dhanbad

NOTICE INVITING EXPRESSION OF INTEREST
The Maithon Power Limited invites expression of interest from eligible vendors for the following packages:

Sl. No.	Tender Description
1	Structural Painting FY-26 at Maithon Power Limited at Maithon Power Limited, Jharkhand (Rate contract for One Year)
2	U#1 NEW LCI COMMISSIONING ACTIVITY at Maithon Power Limited, Jharkhand

For details of pre-qualification requirements, bid security, purchasing of tender document etc., please visit our website URL- <https://www.tatapower.com/tender>
Eligible vendors willing to participate may submit their expression of interest along with the tender fee for issue of bid document latest by 20th Feb 2025.

JUBILANT BIOSYS LIMITED
(CIN: U24110UP1998PLC029591)
Registered Office: Plot 1A, Sector 16A,
Noida, 201301, Uttar Pradesh, India
Tel: +91 120 4361000
Website: www.jubilantbiosys.com

NOTICE
Pursuant to the provisions of Section 201 of the Companies Act, 2013 ('the Act'), the Company intends to make an application to the Central Government under Section 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Act and the Rules made thereunder, for seeking its approval towards appointment of Mr. Giuliano Perfetti (DIN: 09357368) (Non-Resident) appointed as Chief Executive Officer and Managing Director of the Company for a period of 3 years effective from January 27, 2025 in terms of the approval conferred by the Board of Directors of the Company at its Meeting held on Wednesday, October 23, 2024 and by the Shareholders at their Extra Ordinary General Meeting held on Monday, December 2, 2024.

For Jubilant Biosys Limited
Sd/-
Irfan Ali
Company Secretary
Membership No.: A20129

Date: February 10, 2025
Place: Noida

MIRAE ASSET
Financial Services

MIRAE ASSET FINANCIAL SERVICES (INDIA) PRIVATE LIMITED
CIN: U65999MH2020PTC337638
Registered Office: Unit No. 606, 6th Floor, Windsor Bldg, Off CST Road, Kalina, Santacruz - 400098
Website: www.miraassetfin.com | Email: compliance@miraassetfin.com | Phone: + 91 22 6900 5000

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2024
(Amount in ₹ Lakhs)

Sl. No.	Particulars	Quarter ended		Year ended
		December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	
1	Total Income from Operations	3,756.98	2,133.46	7,174.09
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items*)	174.00	(26.85)	790.61
3	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items*)	174.00	(26.85)	790.61
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items*)	395.28	(72.23)	559.64
5	Total Comprehensive Income for the period	2.39	9.26	(3.84)
6	Paid up Equity Share Capital	33,200.00	33,200.00	33,200.00
7	Reserves (excluding Revaluation Reserve)	1,384.80	200.89	359.21
8	Securities Premium Account	-	-	-
9	Net worth	34,584.80	33,400.89	33,559.21
10	Paid up Debt Capital / Outstanding Debt	82,123.33	29,845.10	50,346.18
11	Outstanding Redeemable Preference Shares	-	-	-
12	Debt Equity Ratio	2.37	0.89	1.50
13	Earnings per Share (of ₹ 10 each) (for continuing and discontinued operations) -			
	1. Basic:	0.12	(0.02)	0.17
	2. Diluted:	0.12	(0.02)	0.17
14	Capital Redemption Reserve	-	-	-
15	Debt Redemption Reserve	-	-	-
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA

- Exceptional and/ or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules/ AS Rules, whichever is applicable.

Notes:
a) The above is an extract of the detailed format of quarterly financial results filed with the BSE Limited under regulation 52 of the Listing Regulations. The full format of the quarterly financial results is available on the website of the BSE Limited (www.bseindia.com) and the Company (www.miraassetfin.com).
b) For the other line items referred in regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the BSE Limited and can be accessed on the URL (www.bseindia.com)

For and on behalf of the Board of Directors of
Mirae Asset Financial Services (India) Private Limited
Sd/-
Kishna Kanhaiya
Director & CEO
DIN: 07919729

Place: Mumbai
Date: February 07, 2025

Balaxi Pharmaceuticals Limited

Registered Office: Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598 | Phone: +91 40 23555300 | Email: secretarial@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024
(Rs. in Lakhs unless specified)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter Ended 31.12.2024	Nine Months Ended 31.12.2024	Quarter Ended 31.12.2023	Quarter Ended 31.12.2024	Nine Months Ended 31.12.2024	Quarter Ended 31.12.2023
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited
1	Total Income from Operations	1,115.83	5,133.94	1,269.99	7,329.13	21,629.51	6,078.50
2	Net profit/(loss) for the period (before tax, exceptional* and/or extraordinary items)	233.44	642.66	76.65	606.92	1,900.69	1,263.19
3	Net profit/(loss) for the period before tax (after exceptional* and/or extraordinary items)	233.44	642.66	76.65	606.92	1,900.69	1,427.30
4	Net profit/(loss) for the period after tax (after exceptional* and/or extraordinary items)	174.32	478.13	48.82	536.28	1,643.26	1,359.36
5	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	174.32	478.13	48.82	765.14	1,945.19	953.79
6	Paid-up Equity Share Capital [Face value of Rs. 2 each]	1,104.15	1,104.15	1,023.02	1,104.15	1,104.15	1,023.02
7	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year	-	-	-	-	-	-
8	Earnings Per Share (of Rs.2/- each) 1. Basic (amount in Rs.) 2. Diluted (amount in Rs.)	0.32 0.32	0.87 0.87	0.10 0.09	0.97 0.97	2.98 2.98	2.66 2.64

Notes:
a) The above is an extract of the detailed format of Financial Results for the quarter ended December 31, 2024, filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.
b) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 10, 2025. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of the Board of Directors
Balaxi Pharmaceuticals Limited
Sd/-
Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad
Date: February 10, 2025

This is only an advertisement for information purposes only and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated January 9, 2025 (the "Letter of Offer" or "LOF") filed with the Stock Exchanges, namely BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and together with BSE, "Stock Exchanges" and the Securities and Exchange Board of India ("SEBI").

Camlin Fine Sciences Limited
Our Company was incorporated on November 30, 1993, pursuant to certificate of incorporation issued by RoC, as a private limited company under the name of "Camlin Consultants Private Limited". The name of our Company was changed to "Camlin Fine Chemicals Private Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on June 1, 2006. The name of our Company was changed to "Camlin Fine Chemicals Limited" and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC on August 11, 2006. The name of our Company was then changed to "Camlin Fine Sciences Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on August 27, 2011.

Registered Office: Floor 2 to 5, Building "In G. S. Point", Plot No. VIII, Private Layout Scheme, Opp. University Campus, C.S.T. Road, Kalina, Santacruz (East), Mumbai, Maharashtra, 400098 Contact person: Rahul Sawale, Company Secretary and Compliance Officer
Registered Office Telephone: +91 022 6700 1000 | E-mail id: secretarial@camlinfs.com | Website: https://www.camlinfs.com
Corporate Identity Number: L74100MH1993PLC075361

PROMOTERS OF OUR COMPANY: ASHISH DANDEKAR, ANAGHA DANDEKAR, CAMART FINANCE LIMITED, VIBHA AGENCIES PRIVATE LIMITED, CAFCO CONSULTANTS LIMITED, MK FALCON AGRO TECH PRIVATE LIMITED, INFINITY HOLDINGS, INFINITY DIRECT HOLDINGS, INFINITY DIRECT HOLDINGS SIDECAR I, INFINITY PORTFOLIO HOLDINGS AND ANFIMA NV

ISSUE OF 2,04,25,805 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹1 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹10/- PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹10/- PER RIGHTS EQUITY SHARE) AGGREGATING TO ₹ 2,24,68,38,550/- ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 5 (FIVE) RIGHTS EQUITY SHARES FOR EVERY 41 (FORTY-ONE) FULLY PAID UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS WEDNESDAY, JANUARY 8, 2025 ("RECORD DATE") (THE "ISSUE").

BASIS OF ALLOTMENT
The Board of Directors of Camlin Fine Sciences Limited wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on January 17, 2025 and closed on January 27, 2025 with the last date for on-market renunciation of Rights Entitlements on January 21, 2025. Out of the total 7,420 Applications for 3,39,18,255 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA"), 443 Applications for 4,77,265 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 6,977 Applications for 3,34,40,990 Rights Equity Shares, which was 163.72% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on January 30, 2025 by the Company, in consultation with the Lead Managers, the Registrar to the Issue and BSE, the Designated Stock Exchange for the Issue. The Securities Issue and Allotment Committee of the Company, passed the resolution on January 31, 2025 to record the Basis of Allotment and approved the allotment of 2,04,25,805 Right Equity Shares to successful Applicants. In the Issue, 439 Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and technical rejections have been considered for Allotment.

1. Information regarding Applications received (including ASBA applications received):

Category	Applications Received		Equity Shares Applied for		Equity Shares allotted	
	Number	%	Number	Value (Rs.)	Number	Value (Rs.)
Non Renounees	7,335	98.85%	3,12,94,291	3,44,23,72,010.00	92.26%	1,89,24,596
Renounees	85	1.15%	26,23,964	28,86,36,040.00	7.74%	15,01,209
Total	7,420	100.00%	3,39,18,255	3,73,10,08,050.00	100.00%	2,04,25,805

2. Basis of Allotment:

Category	No. of valid CAFs (including ASBA applications) received	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
	Number	Number	Number	Number
Non Renounees	6,899	1,55,36,785	33,87,811	1,89,24,596
Renounees	85	15,01,209	0	15,01,209
Total	6,984	1,70,37,994	33,87,811	2,04,25,805

Intimations for Allotment / unblock / rejection cases: The dispatch of Allotment Advice cum Unlocking intimation to the investors, as applicable, commenced and completed on February 7, 2025. The instructions to SCSBs for unlocking of funds in case of ASBA Applications were given on January 30, 2025. The listing application was filed with Stock Exchanges on February 3, 2025 and subsequently the listing approvals were received from both BSE and NSE on February 5, 2025 and February 6, 2025, respectively. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on February 7, 2025. For further details, see "TERMS OF ISSUE - ALLOTMENT ADVICE OR REFUND/ UNBLOCKING OF ASBA" on page 312 of the Letter of Offer. Upon receipt of listing and trading approvals, the Rights Equity Shares Allotted in the Issue will commence trading on or before February 11, 2025 and shall be traded under the same ISIN INE052I01032 as the existing Equity Shares. In accordance with the SEBI circular bearing reference No SEBI/HO/CFD/DIL2/CIR/PI/2020/13 dated January 22, 2020 the request for extinguishment of rights entitlement has been sent to NSDL & CDSL on February 6, 2025.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

DISCLAIMER CLAUSE OF SEBI: Submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 276 of the LOF.

DISCLAIMER CLAUSE OF BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE Limited should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of BSE" beginning on page 280 of the LOF.

DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer clause of NSE" on page 280 of the LOF.

LEAD MANAGERS TO THE ISSUE

CENTRUM Centrum Capital Limited Level 9, Centrum House, C.S.T Road, Vidyanageri Marg Kalina, Santacruz East, Mumbai 400098 Telephone: +91 22 4215 9000; E-mail: camlin.rights@centrum.co.in Investor grievance e-mail id: igmbd@centrum.co.in Contact person: Pooja Sanghvi/Tarun Parmari Website: www.centrum.co.in; SEBI Registration No: INM000010445	InCred Capital InCred Capital Wealth Portfolio Managers Private Limited Unit No 1203, 12th Floor, B Wing, The Capital C-70, G Block, BKC, Bandra (E), Mumbai 400051 Telephone: +91-22-4161-1500; E-mail: camlinrights@incredcapital.com Investor grievance e-mail id: customer.grievance@incredcapital.com Contact person: Harish Mallawar; Website: https://www.incredcapital.com/ SEBI Registration No: INM000012865
--	--

REGISTRAR TO THE ISSUE
MUFG
MUFG Intime India Private Limited
(Previously known as, "Link Intime India Private Limited")
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai 400 083, Maharashtra, India
Telephone: +91 81081 14949; Email: camlin.rights@linkintime.co.in
Investor grievance e-mail: camlin.rights@linkintime.co.in
Contact person: Shanti Gopalakrishnan
Website: www.linkintime.co.in; SEBI Registration No.: INR000004058

COMPANY SECRETARY AND COMPLIANCE OFFICER
Rahul Sawale
Floor 2 to 5, Building in G.S. Point, Plot No. VIII, Opp. University Campus,
C.S.T. Road, Kalina, Santacruz East, Mumbai 400098
Telephone: +91 9920882621; E-mail: rahul.sawale@camlinfs.com
Investors may contact the Registrar to the Issue or our Company Secretary and Compliance Officer for any pre issue or post-issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCSB, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/ first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCSB where the Application Form, or the plain paper application, as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, please see "Terms of the Issue" on page 285 of this LOF.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF CAMLIN FINE SCIENCES LIMITED.

For CAMLIN FINE SCIENCES LIMITED
On behalf of the Board of Directors
Sd/-
Rahul Sawale
Company Secretary and Compliance Officer

Date : February 10, 2025
Place : Mumbai

Camlin Fine Sciences Limited has filed a Letter of Offer dated January 9, 2025 with BSE, the designated stock exchange, NSE and SEBI. The LOF is available on the website of SEBI at www.sebi.gov.in, National Stock Exchange of India Limited at www.nseindia.com, BSE Limited at www.bseindia.com, the website of the Lead Managers to the Issue, i.e., Centrum Capital Limited at www.centrum.co.in and InCred Capital Wealth Portfolio Managers Private Limited at https://www.incredcapital.com/, website of the Company at https://www.camlinfs.com and website of the Registrar at www.linkintime.co.in. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 26 of the LOF.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer for sale in any jurisdiction, including United States. The Rights Entitlements and the Right Equity Shares have not been, and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Rights Entitlements (including their credit) and the Right Equity Shares are only being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

CONCEPT

Muthoot Vehicle & Asset Finance Ltd
Corporate Identity Number: U65910KL1992PLC006544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024
₹ in lakhs

Particulars	Quarter Ended		Year Ended
	31 st December 2024	31 st December 2023	31 st March 2024
	Unaudited	Unaudited	Audited
1 Total Income from operations	1,580.16	1,507.87	5,990.29
2 Net Profit for the period (before Tax, Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
3 Net Profit for the period before Tax (after Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
4 Net Profit for the period after Tax (after Exceptional and / or Extraordinary items)	230.98	236.60	1,229.27
5 Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	237.57	243.42	1,222.25
6 Paid up Equity Share Capital (Face Value of Rs. 10/- Each)	2,500.00	2,500.00	2,500.00
7 Other Equity excluding Revaluation Reserves	9,063.46	7,870.96	8,406.83
8 Securities Premium Account	-	-	-
9 Net Worth	11,563.46	10,370.96	10,906.83
10 Paid up Debt Capital / Outstanding Debt	24,402.43	18,022.16	19,583.08
11 Outstanding Redeemable Preference Shares	-	-	-
12 Debt Equity Ratio	2.11	1.74	1.80
13 Earnings per equity share (Face Value of Rs. 10/- Each) (for continuing and discontinued operations) Basic (Rs.)* Diluted (Rs.)*	0.92 0.92	0.95 0.95	4.92 4.92
14 Capital Redemption Reserve	NA	NA	NA
15 Debenture Redemption Reserve	NA	NA	NA
16 Debt Service Coverage Ratio	NA	NA	NA
17 Interest Service Coverage Ratio	NA	NA	NA
*Not annualised			

Note :
a) The above is an extract of the detailed format of Audited Financial Results filed with Stock Exchanges under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the website of BSE Limited (www.bseindia.com) where the Securities of the Company are listed and on the website of the Company at www.mvaf.com
b) For the other line items referred in regulation 52(4) of the Listing Regulation, pertinent disclosures have been made to the BSE limited and can be accessed on www.bseindia.com
c) These financial results have been prepared in accordance with Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulation 2015, as amended

For and on behalf of the Board of Directors
Sd/-
Manoj Jacob
Whole-time Director
DIN : 00019016

Place: Cochin
Date : 10.02.2025

Muthoot Vehicle & Asset Finance Limited
Registered Office: Muthoot Chambers, Opp. Saritha Theatre, Banerji Road, Kochi, Ernakulam - 682 018, Kerala, India;
Corporate Office: 5th and 6th Floor Midhun Tower, K P Vallon Road, Kadavanthra, Ernakulam - 682020, Kerala, India
Tel: +91 75938 64418
Email: cs@mvaf.com, Website: www.mvaf.com
Muthoot Family - 800 years of Business Legacy

Camlin Fine Sciences Limited has filed a Letter of Offer dated January 9, 2025 with BSE, the designated stock exchange, NSE and SEBI. The LOF is available on the website of SEBI at www.sebi.gov.in, National Stock Exchange of India Limited at www.nseindia.com, BSE Limited at www.bseindia.com, the website of the Lead Managers to the Issue, i.e., Centrum Capital Limited at www.centrum.co.in and InCred Capital Wealth Portfolio Managers Private Limited at https://www.incredcapital.com/, website of the Company at https://www.camlinfs.com and website of the Registrar at www.linkintime.co.in. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 26 of the LOF.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer for sale in any jurisdiction, including United States. The Rights Entitlements and the Right Equity Shares have not been, and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Rights Entitlements (including their credit) and the Right Equity Shares are only being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

CONCEPT

MPL
MAITHON POWER LIMITED
MAITHON POWER LIMITED
(Contracts Department)
Maithon Power Ltd, Village: Dambhul,
PO Barbindia, PIN-828205, District-Dhanbad

NOTICE INVITING EXPRESSION OF INTEREST
The Maithon Power Limited invites expression of interest from eligible vendors for the following packages:

Sl. No.	Tender Description
1	Structural Painting FY-26 at Maithon Power Limited at Maithon Power Limited, Jharkhand (Rate contract for One Year)
2	U#1 NEW LCI COMMISSIONING ACTIVITY at Maithon Power Limited, Jharkhand

For details of pre-qualification requirements, bid security, purchasing of tender document etc., please visit our website URL- <https://www.tatapower.com/tender>
Eligible vendors willing to participate may submit their expression of interest along with the tender fee for issue of bid document latest by 20th Feb 2025.

JUBILANT BIOSYS LIMITED
(CIN: U24110UP1998PLC029591)
Registered Office: Plot 1A, Sector 16A,
Noida, 201301, Uttar Pradesh, India
Tel: +91 120 4361000
Website: www.jubilantbiosys.com

NOTICE
Pursuant to the provisions of Section 201 of the Companies Act, 2013 ('the Act'), the Company intends to make an application to the Central Government under Section 196, 197, 203 read with Schedule V and other applicable provisions, if any, of the Act and the Rules made thereunder, for seeking its approval towards appointment of Mr. Giuliano Perfetti (DIN: 09357368) (Non-Resident) appointed as Chief Executive Officer and Managing Director of the Company for a period of 3 years effective from January 27, 2025 in terms of the approval conferred by the Board of Directors of the Company at its Meeting held on Wednesday, October 23, 2024 and by the Shareholders at their Extra Ordinary General Meeting held on Monday, December 2, 2024.

For Jubilant Biosys Limited
Sd/-
Irfan Ali
Company Secretary
Membership No.: A20129

Date: February 10, 2025
Place: Noida

MIRAE ASSET
Financial Services
MIRAE ASSET FINANCIAL SERVICES (INDIA) PRIVATE LIMITED
CIN: U65999MH2020PTC337638
Registered Office: Unit No. 606, 6th Floor, Windsor Bldg, Off CST Road, Kalina, Santacruz - 400098
Website: www.miraassetfin.com | Email: compliance@miraassetfin.com | Phone: + 91 22 6900 5000

EXTRACT OF THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2024 (Amount in ₹ Lakhs)

Sl. No.	Particulars	Quarter ended		Year ended
		December 31, 2024 (Unaudited)	December 31, 2023 (Unaudited)	
1	Total Income from Operations	3,756.98	2,133.46	7,174.09
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary Items)*	174.00	(26.85)	790.61
3	Net Profit / (Loss) for the period before Tax (after Exceptional and / or Extraordinary Items)*	174.00	(26.85)	790.61
4	Net Profit / (Loss) for the period after Tax (after Exceptional and / or Extraordinary Items)*	395.28	(72.23)	559.64
5	Total Comprehensive Income for the period	2.39	9.26	(3.84)
6	Paid up Equity Share Capital	33,200.00	33,200.00	33,200.00
7	Reserves (excluding Revaluation Reserve)	1,384.80	200.89	359.21
8	Securities Premium Account	-	-	-
9	Net worth	34,584.80	33,400.89	33,559.21
10	Paid up Debt Capital / Outstanding Debt	82,123.33	29,845.10	50,346.18
11	Outstanding Redeemable Preference Shares	-	-	-
12	Debt Equity Ratio	2.37	0.89	1.50
13	Earnings per Share (of ₹ 10 each) (for continuing and discontinued operations) -			
	1. Basic:	0.12	(0.02)	0.17
	2. Diluted:	0.12	(0.02)	0.17
14	Capital Redemption Reserve	-	-	-
15	Debt Redemption Reserve	-	-	-
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA

- Exceptional and/ or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules/ AS Rules, whichever is applicable.

Notes:
a) The above is an extract of the detailed format of quarterly financial results filed with the BSE Limited under regulation 52 of the Listing Regulations. The full format of the quarterly financial results is available on the website of the BSE Limited (www.bseindia.com) and the Company (www.miraassetfin.com).
b) For the other line items referred in regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the BSE Limited and can be accessed on the URL (www.bseindia.com)

For and on behalf of the Board of Directors of
Mirae Asset Financial Services (India) Private Limited
Sd/-
Kishna Kanhaiya
Director & CEO
DIN: 07919729

Place: Mumbai
Date: February 07, 2025

Balaxi Pharmaceuticals Limited

Registered Office: Plot No.409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad, Telangana, India - 500096.
CIN: L25191TG1942PLC121598 | Phone: +91 40 23555300 | Email: secretarial@balaxi.in | Website: www.balaxipharma.in

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024 (Rs. in Lakhs unless specified)

Sl. No.	Particulars	STANDALONE		CONSOLIDATED			
		Quarter Ended 31.12.2024	Nine Months Ended 31.12.2024	Quarter Ended 31.12.2023	Quarter Ended 31.12.2024	Nine Months Ended 31.12.2024	Quarter Ended 31.12.2023
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited
1	Total Income from Operations	1,115.83	5,133.94	1,269.99	7,329.13	21,629.51	6,078.50
2	Net profit/(loss) for the period (before tax, exceptional* and/or extraordinary items)	233.44	642.66	76.65	606.92	1,900.69	1,263.19
3	Net profit/(loss) for the period before tax (after exceptional* and/or extraordinary items)	233.44	642.66	76.65	606.92	1,900.69	1,427.30
4	Net profit/(loss) for the period after tax (after exceptional* and/or extraordinary items)	174.32	478.13	48.82	536.28	1,643.26	1,359.36
5	Total Comprehensive Income for the period [Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax)]	174.32	478.13	48.82	765.14	1,945.19	953.79
6	Paid-up Equity Share Capital [Face value of Rs. 2 each]	1,104.15	1,104.15	1,023.02	1,104.15	1,104.15	1,023.02
7	Reserves (excluding Revaluation Reserve) as per the Audited Balance Sheet of the previous year	-	-	-	-	-	-
8	Earnings Per Share (of Rs.2/- each) 1. Basic (amount in Rs.) 2. Diluted (amount in Rs.)	0.32 0.32	0.87 0.87	0.10 0.09	0.97 0.97	2.98 2.98	2.66 2.64

Notes:
a) The above is an extract of the detailed format of Financial Results for the quarter ended December 31, 2024, filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Statement of Unaudited Standalone and Consolidated Financial Results is available on the website of the Stock Exchange at www.nseindia.com (NSE) and on the Company's website at www.balaxipharma.in.
b) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 10, 2025. The said Financial Results are prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013.

For and on behalf of the Board of Directors
Balaxi Pharmaceuticals Limited
Sd/-
Ashish Maheshwari
Managing Director
DIN: 01575984

Place: Hyderabad
Date: February 10, 2025

This is only an advertisement for information purposes only and not for publication, distribution or release directly or indirectly outside India. This is not an announcement for the offer document. All capitalized terms used and not defined herein shall have the meaning assigned to them in the letter of offer dated January 9, 2025 (the "Letter of Offer" or "LOF") filed with the Stock Exchanges, namely BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") and together with BSE, "Stock Exchanges" and the Securities and Exchange Board of India ("SEBI").

CFS Camlin Fine Sciences

Camlin Fine Sciences Limited

Our Company was incorporated on November 30, 1993, pursuant to certificate of incorporation issued by RoC, as a private limited company under the name of "Camlin Consultants Private Limited". The name of our Company was changed to "Camlin Fine Chemicals Private Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on June 1, 2006. The name of our Company was changed to "Camlin Fine Chemicals Limited" and a fresh certificate of incorporation consequent upon change of name on conversion to public limited company was issued by the RoC on August 11, 2006. The name of our Company was then changed to "Camlin Fine Sciences Limited" and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on August 27, 2011.

Registered Office: Floor 2 to 5, Building "In G. S. Point", Plot No. VIII, Private Layout Scheme, Opp. University Campus, C.S.T. Road, Kalina, Santacruz (East), Mumbai, Maharashtra, 400098 Contact person: Rahul Sawale, Company Secretary and Compliance Officer
Registered Office Telephone: +91 022 6700 1000 | E-mail id: secretarial@camlinfo.com | Website: https://www.camlinfo.com
Corporate Identity Number: L74100MH1993PLC075361

PROMOTERS OF OUR COMPANY: ASHISH DANDEKAR, ANAGHA DANDEKAR, CAMART FINANCE LIMITED, VIBHA AGENCIES PRIVATE LIMITED, CAFCO CONSULTANTS LIMITED, MK FALCON AGRO TECH PRIVATE LIMITED, INFINITY HOLDINGS, INFINITY DIRECT HOLDINGS, INFINITY DIRECT HOLDINGS SIDECAR I, INFINITY PORTFOLIO HOLDINGS AND ANFIMA NV

ISSUE OF 2,04,25,805 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹1 EACH OF OUR COMPANY (THE "RIGHTS EQUITY SHARES") FOR CASH AT A PRICE OF ₹110/- PER RIGHTS EQUITY SHARE (INCLUDING A PREMIUM OF ₹109/- PER RIGHTS EQUITY SHARE) AGGREGATING TO ₹2,24,68,38,550/- ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 5 (FIVE) RIGHTS EQUITY SHARES FOR EVERY 41 (FORTY-ONE) FULLY PAID UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS WEDNESDAY, JANUARY 8, 2025 ("RECORD DATE") (THE "ISSUE").

BASIS OF ALLOTMENT

The Board of Directors of Camlin Fine Sciences Limited wishes to thank all its Equity Shareholders, members and investors for their response to the Issue which opened for subscription on January 17, 2025 and closed on January 27, 2025 with the last date for on-market renunciation of Rights Entitlements on January 21, 2025. Out of the total 7,420 Applications for 3,39,18,255 Rights Equity Shares, through the Application Supported by Blocked Amount ("ASBA"), 443 Applications for 4,77,265 Rights Equity Shares were rejected due to technical reasons as disclosed in the Letter of Offer. The total number of valid Applications received were 6,977 Applications for 3,34,40,980 Rights Equity Shares, which was 163.72% of the number of Rights Equity Shares Allotted under the Issue. In accordance with the Letter of Offer, the Basis of Allotment was finalised on January 30, 2025 by the Company, in consultation with the Lead Managers, the Registrar to the Issue and BSE, the Designated Stock Exchange for the Issue. The Securities Issue and Allotment Committee of the Company, passed the resolution on January 31, 2025 to take on record the Basis of Allotment and approved the allotment of 2,04,25,805 Right Equity Shares to successful Applicants. In the Issue, 439 Rights Equity Shares have been kept in abeyance. All valid Applications after the rejection of bids received from non-Eligible Shareholders and technical rejections have been considered for Allotment.

Category	Applications Received		Equity Shares Applied for		Equity Shares Allotted	
	Number	%	Number	Value (₹)	Number	Value (₹)
Non Renounees	7,420	98.85%	1,09,800	11,87,80,000	92,286	10,15,08,800
Renounees	85	1.15%	2,27,000	24,90,50,000	7,744	8,51,30,000
Total	7,505	100.00%	1,10,075	12,11,30,000	100,030	11,03,38,800

Category	No. of valid ASBA applications received (including ASBA applications received)	No. of Equity Shares accepted and allotted against Entitlement (A)	No. of Equity Shares accepted and allotted against Additional applied (B)	Total Equity Shares accepted and allotted (A+B)
Non Renounees	7,420	92,286	0	92,286
Renounees	85	1,09,800	0	1,09,800
Total	7,505	1,09,800	0	1,09,800

Intimations for Allotment / unblock / rejection cases: The dispatch of Allotment Advice cum Unlocking intimation to the investors, as applicable, commenced and completed on February 7, 2025. The instructions to SCBSs for unblocking of funds in case of ASBA Applications were given on January 30, 2025. The listing application was filed with Stock Exchanges on February 3, 2025 and subsequently the listing approvals were received from both BSE and NSE on February 5, 2025 and February 6, 2025, respectively. The credit of Rights Equity Shares in dematerialized form to respective demat accounts of Allottees was completed on February 7, 2025. For further details, see "TERMS OF ISSUE - ALLOTMENT ADVICE OR REFUND/ UNBLOCKING OF ASBA" on page 312 of the Letter of Offer. Upon receipt of listing and trading approvals, the Rights Equity Shares Allotted in the Issue will commence trading on or before February 11, 2025 and shall be traded under the same ISIN INE05201032 as the existing Equity Shares. In accordance with the SEBI circular bearing reference No SEBI/HO/CFD/DIL2/CIR/PI/2020/13 dated January 22, 2020 the request for extinguishment of rights entitlement has been sent to NSDL & CDSL on February 6, 2025.

INVESTORS MAY PLEASE NOTE THAT THE RIGHTS EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM.

DISCLAIMER CLAUSE OF SEBI: Submission of the LOF to SEBI should not in any way be deemed or construed that SEBI has cleared or approved the LOF. Investors are advised to refer to the full text of the "Disclaimer Clause of SEBI" beginning on page 276 of the LOF.

DISCLAIMER CLAUSE OF BSE (Designated Stock Exchange): It is to be distinctly understood that the permission given by BSE Limited should not, in anyway, be deemed or construed that the Letter of Offer has been cleared or approved by BSE Limited; nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of BSE" beginning on page 280 of the LOF.

DISCLAIMER CLAUSE OF NSE: It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the Letter of Offer has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the Letter of Offer. Investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer clause of NSE" on page 280 of the LOF.

LEAD MANAGERS TO THE ISSUE

CENTRUM
Centrum Capital Limited
Unit 9, Centrum House, C.S.T. Road, Vidyanageri Marg
Kalina, Santacruz East, Mumbai 400098
Telephone: +91 22 4215 9000; E-mail: camlin.rights@centrum.co.in
Investor grievance e-mail id: igmbd@centrum.co.in
Contact person: Pooja Sanghvi/Tarun Parmari
Website: www.centrum.co.in; SEBI No: INM00010445

InCred Capital
InCred Capital Wealth Portfolio Managers Private Limited
Unit No 1203, 12th Floor, B Wing, The Capital
C-70, G Block, BKC, Bandra (E), Mumbai 400051
Telephone: +91-22-4161-1500; E-mail: camlin.rights@incredcapital.com
Investor grievance e-mail id: customer.grievance@incredcapital.com
Contact person: Harish Mallawat; Website: https://www.incredcapital.com/ SEBI No: INM00012865

MUFG
MUFG Intime India Private Limited
(Previously known as, "Link Intime India Private Limited")
C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg,
Vikhroli (West) Mumbai 400 083, Maharashtra, India
Telephone: +91 81081 14949; Email: camlin.rights@linkintime.co.in
Investor grievance e-mail: camlin.rights@linkintime.co.in
Contact person: Shanti Gopalakrishnan
Website: www.linkintime.co.in; SEBI Reg No.: INR000004058

REGISTRAR TO THE ISSUE
Rahul Sawale
Floor 2 to 5, Building in G.S. Point, Plot No. VIII, Opp. University Campus,
C.S.T. Road, Kalina, Santacruz East, Mumbai 400098
Telephone: +91 9920882621; E-mail: rahul.sawale@camlinfo.com

Investors may contact the Registrar to the Issue or our Company's Secretary and Compliance Officer for any pre issue or post-issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar to the Issue, with a copy to the SCBS, giving full details such as name, address of the Applicant, contact number(s), e-mail address of the sole/first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked, ASBA Account number and the Designated Branch of the SCBS where the Application Form, or the plain paper application, as the case may be, was submitted by the investors along with a photocopy of the acknowledgement slip. For details on the ASBA process, please see "Terms of the Issue" on page 285 of this LOF.

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES ON LISTING OR THE BUSINESS PROSPECTS OF CAMLIN FINE SCIENCES LIMITED.

For CAMLIN FINE SCIENCES LIMITED
On behalf of the Board of Directors
Sd/-
Rahul Sawale
Company Secretary and Compliance Officer

Date : February 10, 2025
Place : Mumbai

Camlin Fine Sciences Limited has filed a Letter of Offer dated January 9, 2025 with BSE, the designated stock exchange, NSE and SEBI. The LOF is available on the website of SEBI at www.sebi.gov.in, National Stock Exchange of India Limited at www.nseindia.com, BSE Limited at www.bseindia.com, the website of the Lead Managers to the Issue, i.e., Centrum Capital Limited at www.centrum.co.in and InCred Capital Wealth Portfolio Managers Private Limited at https://www.incredcapital.com/, website of the Company at https://www.camlinfo.com and website of the Registrar at www.linkintime.co.in. Investors should note that investment in equity shares involves a degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 28 of the LOF.

This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer for sale in any jurisdiction, including United States. The Rights Entitlements and the Right Equity Shares have not been, and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Rights Entitlements (including their credit) and the Rights Equity Shares are only being offered and sold outside the United States in "offshore transactions" as defined in and in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur.

CONCEPT

Muthoot Vehicle & Asset Finance Ltd
Corporate Identity Number: U65910KL1992PLC006544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024 ₹ in lakhs

Particulars	Quarter Ended		Year Ended
	31 st December 2024	31 st December 2023	31 st March 2024
	Unaudited	Unaudited	Audited
1 Total Income from operations	1,580.16	1,507.87	5,990.29
2 Net Profit for the period (before Tax, Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
3 Net Profit for the period before Tax (after Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
4 Net Profit for the period after Tax (after Exceptional and / or Extraordinary items)	230.98	236.60	1,229.27
5 Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	237.57	243.42	1,222.25
6 Paid up Equity Share Capital (Face Value of Rs. 10/- Each)	2,500.00	2,500.00	2,500.00
7 Other Equity excluding Revaluation Reserves	9,063.46	7,870.96	8,406.83
8 Securities Premium Account	-	-	-
9 Net Worth	11,563.46	10,370.96	10,906.83
10 Paid up Debt Capital / Outstanding Debt	24,402.43	18,022.16	19,583.08
11 Outstanding Redeemable Preference Shares	-	-	-
12 Debt Equity Ratio	2.11	1.74	1.80
13 Earnings per equity share (Face Value of Rs. 10/- Each) (for continuing and discontinued operations) Basic (Rs.)* Diluted (Rs.)*	0.92 0.92	0.95 0.95	4.92 4.92
14 Capital Redemption Reserve	NA	NA	NA
15 Debenture Redemption Reserve	NA	NA	NA
16 Debt Service Coverage Ratio	NA	NA	NA
17 Interest Service Coverage Ratio	NA	NA	NA
*Not annualised			

Note :
a) The above is an extract of the detailed format of Audited Financial Results filed with Stock Exchanges under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the website of BSE Limited (www.bseindia.com) where the Securities of the Company are listed and on the website of the Company at www.mvaf.com
b) For the other line items referred in regulation 52(4) of the Listing Regulation, pertinent disclosures have been made to the BSE limited and can be accessed on www.bseindia.com
c) These financial results have been prepared in accordance with Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulation 2015, as amended

For and on behalf of the Board of Directors
Sd/-
Manoj Jacob
Whole-time Director
DIN : 00019016

Place: Cochin
Date : 10.02.2025

Muthoot Vehicle & Asset Finance Limited
Registered Office: Muthoot Chambers, Opp. Saritha Theatre, Banerji Road, Kochi, Emakulam - 682 018, Kerala, India;
Corporate Office: 5th and 6th Floor Midhun Tower, K P Vallon Road, Kadavanthra, Emakulam - 682020, Kerala, India
Tel: +91 75938 64418
Email: cs@mvafl.com, Website: www.mvafl.com
Muthoot Family - 800 years of Business Legacy

Muthoot Vehicle & Asset Finance Ltd
Corporate Identity Number: U65910KL1992PLC006544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2024 ₹ in lakhs

Particulars	Quarter Ended		Year Ended
	31 st December 2024	31 st December 2023	31 st March 2024
	Unaudited	Unaudited	Audited
1 Total Income from operations	1,580.16	1,507.87	5,990.29
2 Net Profit for the period (before Tax, Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
3 Net Profit for the period before Tax (after Exceptional and / or Extraordinary items)	294.25	319.85	1,593.27
4 Net Profit for the period after Tax (after Exceptional and / or Extraordinary items)	230.98	236.60	1,229.27
5 Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	237.57	243.42	1,222.25
6 Paid up Equity Share Capital (Face Value of Rs. 10/- Each)	2,500.00	2,500.00	2,500.00
7 Other Equity excluding Revaluation Reserves	9,063.46	7,870.96	8,406.83
8 Securities Premium Account	-	-	-
9 Net Worth	11,563.46	10,370.96	10,906.83
10 Paid up Debt Capital / Outstanding Debt	24,402.43	18,022.16	19,583.08
11 Outstanding Redeemable Preference Shares	-	-	-
12 Debt Equity Ratio	2.11	1.74	1.80
13 Earnings per equity share (Face Value of Rs. 10/- Each) (for continuing and discontinued operations) Basic (Rs.)* Diluted (Rs.)*	0.92 0.92	0.95 0.95	4.92 4.92
14 Capital Redemption Reserve	NA	NA	NA
15 Debenture Redemption Reserve	NA	NA	NA
16 Debt Service Coverage Ratio	NA	NA	NA
17 Interest Service Coverage Ratio	NA	NA	NA
*Not annualised			

Note :
a) The above is an extract of the detailed format of Audited Financial Results filed with Stock Exchanges under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results are available on the website of BSE Limited (www.bseindia.com) where the Securities of the Company are listed and on the website of the Company at www.mvaf.com
b) For the other line items referred in regulation 52(4) of the Listing Regulation, pertinent disclosures have been made to the BSE limited and can be accessed on www.bseindia.com
c) These financial results have been prepared in accordance with Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulation 2015, as amended

For and on behalf of the Board of Directors
Sd/-
Manoj Jacob
Whole-time Director
DIN : 00019016

Place: Cochin
Date : 10.02.2025

Muthoot Vehicle & Asset Finance Limited
Registered Office: Muthoot Chambers, Opp. Saritha Theatre, Banerji Road, Kochi, Emakulam - 682 018, Kerala, India;
Corporate Office: 5th and 6th Floor Midhun Tower, K P Vallon Road, Kadavanthra, Emakulam - 682020, Kerala, India
Tel: +91 75938 64418
Email: cs@mvafl.com, Website: www.mvafl.com
Muthoot Family - 800 years of Business Legacy

